Susquehanna International Group, LLP Summit Therapeutics Inc. Call Options Transaction History

Susquehanna International Group, LLP

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 07, 2024	BUY	$2.55 - $5.07 $82,620 - $164,268	32,400 Added 68.79%	79,500 $329,000
Q4 2023 Feb 14, 2024	SELL	$1.67 - $2.83 $893,617 - $1.51 Million	-535,100 Reduced 91.91%	47,100 $122,000
Q3 2023 Nov 14, 2023	BUY	$1.54 - $2.42 $803,726 - $1.26 Million	521,900 Added 865.51%	582,200 $1.09 Million
Q2 2023 Aug 11, 2023	SELL	$1.32 - $2.81 $134,244 - $285,777	-101,700 Reduced 62.78%	60,300 $151,000
Q1 2023 May 16, 2023	SELL	$1.38 - $5.41 $561,522 - $2.2 Million	-406,900 Reduced 71.52%	162,000 $283,000

Q4 2022 Feb 14, 2023	BUY	$0.68 - $5.31 $386,852 - $3.02 Million	568,900 New	568,900 $2.42 Million
Q1 2022 May 16, 2022	SELL	$2.0 - $3.45 $48,600 - $83,835	-24,300 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$2.45 - $5.64 $105,595 - $243,084	-43,100 Reduced 63.95%	24,300 $65,000
Q3 2021 Nov 15, 2021	SELL	$4.83 - $8.27 $192,717 - $329,973	-39,900 Reduced 37.19%	67,400 $338,000
Q2 2021 Aug 11, 2021	BUY	$5.15 - $8.46 $552,595 - $907,758	107,300 New	107,300 $800,000

107

41.3M

103K

29.9K

Ticker SMMT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 201,215,008
Market Cap $1.39B
Description
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.